Home Health Why Pfizer’s newest stumble within the weight problems market is a boon...

Why Pfizer’s newest stumble within the weight problems market is a boon for Eli Lilly

0
42
Why Pfizer’s newest stumble within the weight problems market is a boon for Eli Lilly


Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, Could 3, 2023. Eli Lilly & Co.’s shares climbed in early US buying and selling after its experimental drug for Alzheimer’s slowed the progress of the illness in a final-stage trial, paving the best way for the corporate to use for US approval.

AJ Mast | Bloomberg | Getty Photos

Pfizer (PFE) has suffered one other setback in its efforts to develop a weight-loss capsule — and that is excellent news for Membership holding Eli Lilly (LLY) because it appears to be like to keep up an edge within the fast-growing obesity-treatment market.


#Pfizers #newest #stumble #weight problems #market #boon #Eli #Lilly